Windtree Therapeutics (NASDAQ:WINT) reported quarterly losses of $(4.63) per share which beat the analyst consensus estimate of $(28.82) by 83.93 percent. This is a 100.42 percent decrease over earnings of $1.10 thousand per share from the same period last year.